An investigational treatment for an uncommon immunodeficiency disease races into clinical studies.

Novartis innovation and events such as mHealth Challenge enable patients to access data and personal information about their health via mobile devices.

A diminutive protein prompts a closer look at DNA dark matter.

Novartis-Harvard team identifies a new type of cell that is key to the disease.

Novartis drug hunters leverage machine learning and automation to power a faster, smarter way to navigate to new drugs.

Researchers from industry and academia will leverage new chemistry to hit difficult drug targets.

A new type of medicine that targets RNA was discovered by accident and could change the way some diseases are treated.